SCHEMBL3784878

SCHEMBL3784878

CC(C)(C)OC(=O)NC1CN(C(=O)c2cn3cc(-c4coc(Br)c4)cc(C(F)(F)F)c3n2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.38
ADORA2A P29274 5/20 0.34
ADORA3 P0DMS8 3/20 0.34
ADORA2B P29275 3/20 0.34
ADORA1 P30542 1/20 0.34
NR1H2 P55055 1/20 0.33
ACLY P53396 1/20 0.32
SUV39H2 Q9H5I1 1/20 0.32
ITGB2 P05107 1/20 0.32
ICAM1 P05362 1/20 0.32
ITGAL P20701 1/20 0.32
HDAC4 P56524 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32
PDE4B Q07343 1/20 0.31
PDE11A Q9HCR9 1/20 0.31
PDE10A Q9Y233 1/20 0.31
PARP1 P09874 2/20 0.31
SCN9A Q15858 1/20 0.30
SYK P43405 1/20 0.30
MKNK1 Q9BUB5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3686976 0.86 CFTR (0.42) CFTRADORA2AADORA3ADORA2BADORA1
SCHEMBL13261973 0.85 RBP4 (0.31)
SCHEMBL3784733 0.84 SCN9A (0.38) SCN9A
SCHEMBL3687589 0.84 CFTR (0.39) CFTRADORA2AADORA3ADORA2BADORA1
SCHEMBL13228571 0.83 SCN9A (0.32) SCN9A
SCHEMBL3784934 0.83 SCN9A (0.34) SCN9A
Hydrochloric Acid SCHEMBL3788860 0.82 SCN9A (0.33) SCN9A
SCHEMBL13228574 0.81 SCN9A (0.32) SCN9A
SCHEMBL3792019 0.76 RXFP1 (0.42)
SCHEMBL13261947 0.71 ERN1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204265-A1 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections GENELABS TECHNOLOGIES, INC. 2010-08-12 US disclosed
WO-2010091409-A1 CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed
US-20100204265-A1 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections GENELABS TECHNOLOGIES, INC. 2010-08-12 US disclosed
WO-2010091409-A1 CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed
US-20100204265-A1 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections GENELABS TECHNOLOGIES, INC. 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204265-A1 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections OAT, HAVCR2, CPS1 CFTR 2042/4885ADORA2A 1016/4885ADORA3 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.